Product Program year 2025 Source: CMS Open Payments

Voyxact

Drug Nephrology

NDC 59148-400-75

Open in the dashboard

General payments

$80,631

1,659 payments

Research payments

$0

0 payments

Through program year 2025, $80,631 in general payments and $0 in research payments were reported against Voyxact (Nephrology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Amount Payments
2025 General $80,631 1,659

Breakdown

Who paid General payments · program year 2025
  1. Otsuka America Pharmaceutical, Inc. $74,591 1,534 payments
  2. Otsuka Pharmaceutical Development & Commercialization, Inc. $6,039 125 payments
Top recipients General payments · program year 2025
  1. Donald Molony Nephrology · Houston, TX $7,182 9% · 4 payments
  2. James Chevalier Nephrology · New York, NY $6,802 8% · 10 payments
  3. Osama Amro Nephrology · Seattle, WA $6,659 8% · 10 payments
  4. Nissreen Elfadawy Nephrology · Chardon, OH $6,643 8% · 4 payments
  5. Anjay Rastogi Nephrology · Los Angeles, CA $2,920 4% · 1 payment

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Nephrology Internal Medicine $66,815 84% · 985 practitioners
  2. Nurse Practitioner, Family Nurse Practitioner $3,406 4% · 126 practitioners
  3. Internal Medicine $2,152 3% · 68 practitioners
  4. Nurse Practitioner $1,902 2% · 70 practitioners
  5. Physician Assistant $1,062 1% · 37 practitioners

The top 5 of 33 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Texas $12,229 15% · 127 recipients
  2. New York $11,863 15% · 106 recipients
  3. Ohio $10,896 14% · 63 recipients
  4. California $7,774 10% · 127 recipients
  5. Washington $7,138 9% · 5 recipients

The top 5 of 45 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

1,659 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record